Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Bunchai Chongmelaxme, Nathorn Chaiyakunapruk & Piyameth Dilokthornsakul. (2019) Incorporating adherence in cost-effectiveness analyses of asthma: a systematic review. Journal of Medical Economics 22:6, pages 554-566.
Read now
Read now
Sophie K. Wong, Abby Li, Krista L. Lanctôt & Bosco Paes. (2018) Adherence and outcomes: a systematic review of palivizumab utilization. Expert Review of Respiratory Medicine 12:1, pages 27-42.
Read now
Read now
Mingsheng Chen, Lei Si, Tania M Winzenberg, Jieruo Gu, Qicheng Jiang & Andrew J Palmer. (2016) Cost-effectiveness of raloxifene in the treatment of osteoporosis in Chinese postmenopausal women: impact of medication persistence and adherence. Patient Preference and Adherence 10, pages 415-423.
Read now
Read now
Charles Christian Adarkwah, Paul F. van Gils, Mickaël Hiligsmann & Silvia M.A.A. Evers. (2016) Risk of bias in model-based economic evaluations: the ECOBIAS checklist. Expert Review of Pharmacoeconomics & Outcomes Research 16:4, pages 513-523.
Read now
Read now
Doreen Matsui. (2013) Medication adherence issues in patients: focus on cost. Clinical Audit 5, pages 33-42.
Read now
Read now
Mickaël Hiligsmann, Annelies Boonen, Carmen D Dirksen, Wafa Ben Sedrine & Jean-Yves Reginster. (2013) Cost–effectiveness of denosumab in the treatment of postmenopausal osteoporotic women. Expert Review of Pharmacoeconomics & Outcomes Research 13:1, pages 19-28.
Read now
Read now
Articles from other publishers (37)
Elahe Hesari, Mahnaz Sanjari, Mohammad Javad Mansourzadeh, Noushin Fahimfar, Kazem Khalagi, Arash Ghazbani, Afshin Ostovar & Akbar Fotouhi. (2023) Osteoporosis medication adherence tools: a systematic review. Osteoporosis International 34:9, pages 1535-1548.
Crossref
Crossref
Rebecca J. Moon, Jean-Yves Reginster, Nasser M. Al-Daghri, Jotheeswaran A. Thiyagarajan, Charlotte Beaudart, Olivier Bruyère, Nansa Burlet, Manju Chandran, Mario Coelho da Silva, Philip G. Conaghan, Willard H. Dere, Adolfo Diez-Perez, Peyman Hadji, Philippe Halbout, Mickaël Hiligsmann, John A. Kanis, Eugene V. McCloskey, Sif Ormarsdottir, Daniel Prieto-Alhambra, Régis P. Radermecker, René Rizzoli, Yousef Al-Saleh, Stuart L. Silverman, Lee S. Simon, Friederike Thomasius, Tjeerd van Staa, Andrea Laslop, Cyrus Cooper & Nicholas C. Harvey. (2023) Real-world evidence: new opportunities for osteoporosis research. Recommendations from a Working Group from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Osteoporosis International 34:8, pages 1283-1299.
Crossref
Crossref
Andrew Blauvelt, Nianwen Shi, Russel Burge, Bilal Atiya, Baojin Zhu, Najwa Somani, Terri Ridenour, Carolyn R. Lew, Nicole M. Zimmerman & Mwangi J. Murage. (2022) Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months. PharmacoEconomics - Open 6:6, pages 871-880.
Crossref
Crossref
M. Hiligsmann, S. Maggi, N. Veronese, L. Sartori & J.-Y. Reginster. (2021) Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy. Osteoporosis International 32:3, pages 595-606.
Crossref
Crossref
M. Chandran, G. Ganesan, K.B. Tan, J.-Y. Reginster & M. Hiligsmann. (2020) Cost-effectiveness of FRAX®-based intervention thresholds for management of osteoporosis in Singaporean women. Osteoporosis International 32:1, pages 133-144.
Crossref
Crossref
Charlotte Beaudart, Nannan Li, Mickael Hiligsmann & Stuart Silverman. 2021. Osteoporosis Treatment. Osteoporosis Treatment
115
143
.
Ruxu You & Zijie Liu. (2020) Economic Evaluation of Oral Alendronate Therapy for Osteoporosis in Chinese Postmenopausal Women: The Impact of Medication Compliance and Persistence. Frontiers in Pharmacology 11.
Crossref
Crossref
Md Azharuddin, Mohammad Adil, Rashid Ali Khan, Pinaki Ghosh, Prem Kapur & Manju Sharma. (2020) Systematic evidence of health economic evaluation of drugs for postmenopausal osteoporosis: A quality appraisal. Osteoporosis and Sarcopenia 6:2, pages 39-52.
Crossref
Crossref
M. Hiligsmann, D. Cornelissen, B. Vrijens, B. Abrahamsen, N. Al-Daghri, E. Biver, M.L. Brandi, O. Bruyère, N. Burlet, C. Cooper, B. Cortet, E. Dennison, A. Diez-Perez, A. Gasparik, A. Grosso, P. Hadji, P. Halbout, J.A. Kanis, J.M. Kaufman, A. Laslop, S. Maggi, R. Rizzoli, T. Thomas, S. Tuzun, M. Vlaskovska & J.Y. Reginster. (2019) Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF). Osteoporosis International 30:11, pages 2155-2165.
Crossref
Crossref
Rachelle L Cutler, Naomi Van der Linden, Shalom I (Charlie) Benrimoj, Fernando Fernandez-Llimos & Victoria Garcia-Cardenas. (2019) An evidence-based model to consolidate medication adherence cost estimation: the medication adherence cost estimation framework. Journal of Comparative Effectiveness Research 8:8, pages 555-567.
Crossref
Crossref
M. Hiligsmann & J.-Y. Reginster. (2019) Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France. Osteoporosis International 30:3, pages 649-658.
Crossref
Crossref
M. Hiligsmann, J.-Y. Reginster, A.N.A. Tosteson, S.V. Bukata, K.G. Saag, D.T. Gold, P. Halbout, F. Jiwa, E.M. Lewiecki, D. Pinto, J.D. Adachi, N. Al-Daghri, O. Bruyère, M. Chandran, C. Cooper, N.C. Harvey, T.A. Einhorn, J.A. Kanis, D.L. Kendler, O.D. Messina, R. Rizzoli, L. Si & S. Silverman. (2018) Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts’ consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. Osteoporosis International 30:1, pages 45-57.
Crossref
Crossref
Margret V. Bjarnadottir, David Czerwinski & Eberechukwu Onukwugha. (2017) Sensitivity of the Medication Possession Ratio to Modelling Decisions in Large Claims Databases. PharmacoEconomics 36:3, pages 369-380.
Crossref
Crossref
Hajime Orimo, Masayo Sato, Shuichi Kimura, Keiko Wada, Xuelu Chen, Shigeto Yoshida & Bruce Crawford. (2017) Understanding the factors associated with initiation and adherence of osteoporosis medication in Japan: An analysis of patient perceptions. Osteoporosis and Sarcopenia 3:4, pages 174-184.
Crossref
Crossref
Julie C. Lauffenburger, Joan E. Landon & Michael A. Fischer. (2017) Effect of Combination Therapy on Adherence Among US Patients Initiating Therapy for Hypertension: a Cohort Study. Journal of General Internal Medicine 32:6, pages 619-625.
Crossref
Crossref
L. Si, T. M. Winzenberg, M. Chen, Q. Jiang, A. Neil & A. J. Palmer. (2016) Screening for osteoporosis in Chinese post-menopausal women: a health economic modelling study. Osteoporosis International 27:7, pages 2259-2269.
Crossref
Crossref
O. Ethgen, M. Hiligsmann, N. Burlet & J.-Y. Reginster. (2015) Cost-effectiveness of personalized supplementation with vitamin D-rich dairy products in the prevention of osteoporotic fractures. Osteoporosis International 27:1, pages 301-308.
Crossref
Crossref
Annemarie van der Kolk, Clazien AM Bouwmans, Saskia J Schawo, Jan K Buitelaar, Michel van Agthoven & Leona Hakkaart-van Roijen. (2015) Association between societal costs and treatment response in children and adolescents with ADHD and their parents. A cross-sectional study in the Netherlands. SpringerPlus 4:1.
Crossref
Crossref
Olivier Ethgen, Mickaël Hiligsmann, Nansa Burlet & Jean-Yves Reginster. (2015) Public health impact and cost-effectiveness of dairy products supplemented with vitamin D in prevention of osteoporotic fractures. Archives of Public Health 73:1.
Crossref
Crossref
Jameel Nazir, Lars Heemstra, Anke van Engen, Zalmai Hakimi & Cristina Ivanescu. (2015) Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia. BMC Urology 15:1.
Crossref
Crossref
L. Karlsson, J. Lundkvist, E. Psachoulia, M. Intorcia & O. Ström. (2015) Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporosis International 26:10, pages 2401-2411.
Crossref
Crossref
Poliana F Oliveira Mirna & Rita C G Novaes Maria. (2015) Pharmacotherapy follow-up in elderly in a public outpatient clinic in Brasilia, Brazil. African Journal of Pharmacy and Pharmacology 9:32, pages 818-833.
Crossref
Crossref
M. L. Bianchi, P. Duca, S. Vai, G. Guglielmi, R. Viti, C. Battista, A. Scillitani, S. Muscarella, G. Luisetto, V. Camozzi, R. Nuti, C. Caffarelli, S. Gonnelli, C. Albanese, V. De Tullio, G. Isaia, P. D’Amelio, F. Broggi & M. Croci. (2015) Improving adherence to and persistence with oral therapy of osteoporosis. Osteoporosis International 26:5, pages 1629-1638.
Crossref
Crossref
L. Si, T. M. Winzenberg, Q. Jiang & A. J. Palmer. (2015) Screening for and treatment of osteoporosis: construction and validation of a state-transition microsimulation cost-effectiveness model. Osteoporosis International 26:5, pages 1477-1489.
Crossref
Crossref
Mickaël Hiligsmann, Silvia M. Evers, Wafa Ben Sedrine, John A. Kanis, Bram Ramaekers, Jean-Yves Reginster, Stuart Silverman, Caroline E. Wyers & Annelies Boonen. (2014) A Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis. PharmacoEconomics 33:3, pages 205-224.
Crossref
Crossref
Kevin B. Sneed. 2015. Hypertension in High Risk African Americans. Hypertension in High Risk African Americans
199
212
.
John A. Kanis & Mickaël Hiligsmann. (2014) The application of health technology assessment in osteoporosis. Best Practice & Research Clinical Endocrinology & Metabolism 28:6, pages 895-910.
Crossref
Crossref
Andrea Ildiko Gasparik. (2014) Clinical Setting Influences Patterns of Interaction between Osteoporosis Patient and Physician. Calcified Tissue International 95:2, pages 122-124.
Crossref
Crossref
Jelena Stevanović, Anouk C. O’Prinsen, Bram G. Verheggen, Nynke Schuiling-Veninga, Maarten J. Postma & Petros Pechlivanoglou. (2014) Economic Evaluation of Primary Prevention of Cardiovascular Diseases in Mild Hypertension: A Scenario Analysis for the Netherlands. Clinical Therapeutics 36:3, pages 368-384.e5.
Crossref
Crossref
E. M. Clark, L. Carter, V. C. Gould, L. Morrison & J. H. Tobias. (2013) Vertebral fracture assessment (VFA) by lateral DXA scanning may be cost-effective when used as part of fracture liaison services or primary care screening. Osteoporosis International 25:3, pages 953-964.
Crossref
Crossref
Bing-Bing Qi & Barbara Resnick. (2014) Reliability and Validity of the Chinese Versions of Self-Efficacy and Outcome Expectations for Osteoporosis Medication Adherence Scales in Chinese Immigrants. Journal of Nursing Measurement 22:3, pages 472-488.
Crossref
Crossref
Mickael Hiligsmann, John A. Kanis, Juliet Compston, Cyrus Cooper, Bruno Flamion, Pierre Bergmann, Jean-Jacques Body, Steven Boonen, Olivier Bruyere, Jean-Pierre Devogelaer, Stefan Goemaere, Jean-Marc Kaufman, Serge Rozenberg & Jean-Yves Reginster. (2013) Health Technology Assessment in Osteoporosis. Calcified Tissue International 93:1, pages 1-14.
Crossref
Crossref
Mickael Hiligsmann, Wafa Ben Sedrine & Jean‐Yves Reginster. (2013) Cost‐effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women. Journal of Bone and Mineral Research 28:4, pages 807-815.
Crossref
Crossref
Ikuko Tanaka, Masayo Sato, Tomoko Sugihara, Douglas E. Faries, Shuko Nojiri, Peita Graham-Clarke, Jennifer A. Flynn & Russel T. Burge. (2013) Adherence and Persistence with Once-Daily Teriparatide in Japan: A Retrospective, Prescription Database, Cohort Study. Journal of Osteoporosis 2013, pages 1-8.
Crossref
Crossref
Ananth Kadambi, Robert J. Leipold, Anuraag R. Kansal, Sonja Sorensen & Denis Getsios. (2012) Inclusion of Compliance and Persistence in Economic Models. Applied Health Economics and Health Policy 10:6, pages 365-379.
Crossref
Crossref
Ananth Kadambi, Robert J. Leipold, Anuraag R. Kansal, Sonja Sorensen & Denis Getsios. (2012) Inclusion of Compliance and Persistence in Economic Models. Applied Health Economics and Health Policy 10:6, pages 365-379.
Crossref
Crossref
Javier Soto ÁlvarezJavier Soto Álvarez. 2012. Evaluación económica de medicamentos y tecnologías sanitarias:. Evaluación económica de medicamentos y tecnologías sanitarias:
305
324
.